{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T04:06:33Z","timestamp":1788926793706,"version":"build-2803163510"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03355-x","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:45:45Z","timestamp":1786077945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Current status and challenges of immune checkpoint inhibitors in liver cancer: from monotherapy to combination strategies"],"prefix":"10.1007","volume":"43","author":[{"given":"Miao","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2055-1024","authenticated-orcid":false,"given":"Congyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"1","key":"3355_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/17843286.2020.1778346","volume":"77","author":"T De Somer","year":"2022","unstructured":"De Somer T, Vanderstraeten E, Bouderez V, Monsaert E, Van Steenkiste C. Resolution of a hepatoduodenal fistula after nivolumab treatment in a patient with hepatocellular carcinoma: challenges in immunotherapy. Acta Clin Belg. 2022;77(1):108\u201312. https:\/\/doi.org\/10.1080\/17843286.2020.1778346.","journal-title":"Acta Clin Belg"},{"issue":"20","key":"3355_CR2","doi-asserted-by":"publisher","first-page":"5072","DOI":"10.3390\/cancers15205072","volume":"15","author":"Y Tamai","year":"2023","unstructured":"Tamai Y, Fujiwara N, Tanaka T, Mizuno S, Nakagawa H. Combination Therapy of Immune Checkpoint Inhibitors with Locoregional Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2023;15(20):5072. https:\/\/doi.org\/10.3390\/cancers15205072. Published 2023 Oct 20.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"3355_CR3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1007\/s12094-024-03644-9","volume":"27","author":"Y Lu","year":"2025","unstructured":"Lu Y, Lu Y. Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer. Clin Transl Oncol. 2025;27(3):1142\u201354. https:\/\/doi.org\/10.1007\/s12094-024-03644-9.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"3355_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12935-023-03051-0","volume":"23","author":"R Han","year":"2023","unstructured":"Han R, Ling C, Wang Y, Lu L. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1\/PD-L1 inhibition. Cancer Cell Int. 2023;23(1):203. https:\/\/doi.org\/10.1186\/s12935-023-03051-0. Published 2023 Sep 16.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"3355_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s11912-022-01247-7","volume":"24","author":"KM Wong","year":"2022","unstructured":"Wong KM, King GG, Harris WP. The Treatment Landscape of Advanced Hepatocellular Carcinoma. Curr Oncol Rep. 2022;24(7):917\u201327. https:\/\/doi.org\/10.1007\/s11912-022-01247-7.","journal-title":"Curr Oncol Rep"},{"key":"3355_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejim.2022.12.025","volume":"111","author":"B Zhang","year":"2023","unstructured":"Zhang B, Tao B, Li Y, et al. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma. Eur J Intern Med. 2023;111:37\u201346. https:\/\/doi.org\/10.1016\/j.ejim.2022.12.025.","journal-title":"Eur J Intern Med"},{"key":"3355_CR7","doi-asserted-by":"publisher","unstructured":"Dai S, Chen Y, Cai W et al. Combination immunotherapy in hepatocellular carcinoma: synergies among immune checkpoints, TKIs, and chemotherapy. J Hematol Oncol. 2025;18(1):85. Published 2025 Sep 26. https:\/\/doi.org\/10.1186\/s13045-025-01739-6","DOI":"10.1186\/s13045-025-01739-6"},{"key":"3355_CR8","doi-asserted-by":"publisher","unstructured":"Wang M, Sun M, Dong H, et al. Elemene Augments the Effects of Anti-PD-1 Immunotherapy on Hepatocellular Carcinoma by Regulating the miR-130a-5p\/SPP\/MHC-I Axis. Adv Sci (Weinh). Published online January. 2026;12. https:\/\/doi.org\/10.1002\/advs.202511887.","DOI":"10.1002\/advs.202511887"},{"key":"3355_CR9","doi-asserted-by":"publisher","first-page":"958720","DOI":"10.3389\/fonc.2022.958720","volume":"12","author":"Q Xie","year":"2022","unstructured":"Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol. 2022;12:958720. https:\/\/doi.org\/10.3389\/fonc.2022.958720. Published 2022 Sep 2.","journal-title":"Front Oncol"},{"key":"3355_CR10","doi-asserted-by":"publisher","first-page":"1197698","DOI":"10.3389\/fonc.2023.1197698","volume":"13","author":"S Xie","year":"2023","unstructured":"Xie S, Wang M, Zeng C, et al. Research progress of targeted therapy combined with immunotherapy for hepatocellular. Front Oncol. 2023;13:1197698. https:\/\/doi.org\/10.3389\/fonc.2023.1197698. Published 2023 May 25.","journal-title":"Front Oncol"},{"issue":"17","key":"3355_CR11","doi-asserted-by":"publisher","first-page":"6798","DOI":"10.7150\/thno.102995","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang J, Chen Y, Xu Y, et al. DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma. Theranostics. 2024;14(17):6798\u2013817. https:\/\/doi.org\/10.7150\/thno.102995. Published 2024 Oct 14.","journal-title":"Theranostics"},{"key":"3355_CR12","doi-asserted-by":"publisher","unstructured":"Xu J, Li J, Wang T et al. Predicting treatment response and prognosis of immune checkpoint inhibitors-based combination therapy in advanced hepatocellular carcinoma using a longitudinal CT-based radiomics model: a multicenter study. BMC Cancer. 2025;25(1):602. Published 2025 Apr 3. https:\/\/doi.org\/10.1186\/s12885-025-13978-4","DOI":"10.1186\/s12885-025-13978-4"},{"issue":"2","key":"3355_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3390\/cancers14020454","volume":"14","author":"S Nishina","year":"2022","unstructured":"Nishina S, Hino K. CD26\/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma. Cancers (Basel). 2022;14(2):454. https:\/\/doi.org\/10.3390\/cancers14020454. Published 2022 Jan 17.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3355_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","volume":"17","author":"KY Shen","year":"2024","unstructured":"Shen KY, Zhu Y, Xie SZ, Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol. 2024;17(1):25. https:\/\/doi.org\/10.1186\/s13045-024-01549-2. Published 2024 Apr 29.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"3355_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1007\/s00262-020-02773-8","volume":"70","author":"L Singh","year":"2021","unstructured":"Singh L, Singh MK, Kenney MC, et al. Prognostic significance of PD-1\/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters. Cancer Immunol Immunother. 2021;70(5):1291\u2013303. https:\/\/doi.org\/10.1007\/s00262-020-02773-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3355_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/13543784.2022.2033208","volume":"31","author":"M Maestri","year":"2022","unstructured":"Maestri M, Pallozzi M, Santopaolo F, et al. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opin Investig Drugs. 2022;31(4):347\u201360. https:\/\/doi.org\/10.1080\/13543784.2022.2033208.","journal-title":"Expert Opin Investig Drugs"},{"key":"3355_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.anndiagpath.2017.04.007","volume":"29","author":"R Alaghehbandan","year":"2017","unstructured":"Alaghehbandan R, Stehlik J, Trpkov K, et al. Programmed death-1 (PD-1) receptor\/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Ann Diagn Pathol. 2017;29:17\u201322. https:\/\/doi.org\/10.1016\/j.anndiagpath.2017.04.007.","journal-title":"Ann Diagn Pathol"},{"issue":"11","key":"3355_CR18","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.4251\/wjgo.v13.i11.1725","volume":"13","author":"Z Deng","year":"2021","unstructured":"Deng Z, Teng YJ, Zhou Q, et al. Shuyu pills inhibit immune escape and enhance chemosensitization in hepatocellular carcinoma. World J Gastrointest Oncol. 2021;13(11):1725\u201340. https:\/\/doi.org\/10.4251\/wjgo.v13.i11.1725.","journal-title":"World J Gastrointest Oncol"},{"issue":"11","key":"3355_CR19","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.5858\/arpa.2017-0516-OA","volume":"142","author":"C Del","year":"2018","unstructured":"Del C, Monroig-Bosque P, Driver B, Morales-Rosado JA, et al. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. Arch Pathol Lab Med. 2018;142(11):1388\u201393. https:\/\/doi.org\/10.5858\/arpa.2017-0516-OA.","journal-title":"Arch Pathol Lab Med"},{"issue":"23","key":"3355_CR20","doi-asserted-by":"publisher","first-page":"16773","DOI":"10.3390\/ijms242316773","volume":"24","author":"P Chami","year":"2023","unstructured":"Chami P, Diab Y, Khalil DN, et al. Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma. Int J Mol Sci. 2023;24(23):16773. https:\/\/doi.org\/10.3390\/ijms242316773. Published 2023 Nov 26.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3355_CR21","doi-asserted-by":"publisher","first-page":"152802","DOI":"10.1016\/j.prp.2019.152802","volume":"216","author":"X Wang","year":"2020","unstructured":"Wang X, Liu Y. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer. Pathol Res Pract. 2020;216(3):152802. https:\/\/doi.org\/10.1016\/j.prp.2019.152802.","journal-title":"Pathol Res Pract"},{"issue":"9","key":"3355_CR22","doi-asserted-by":"publisher","first-page":"e1626653","DOI":"10.1080\/2162402X.2019.1626653","volume":"8","author":"S Kim","year":"2019","unstructured":"Kim S, Nam SJ, Park C, et al. High tumoral PD-L1 expression and low PD-1\u2009<\u2009sup>+\u2009or CD8\u2009<\u2009sup>+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. Oncoimmunology. 2019;8(9):e1626653. https:\/\/doi.org\/10.1080\/2162402X.2019.1626653. Published 2019 Jun 10.","journal-title":"Oncoimmunology"},{"key":"3355_CR23","doi-asserted-by":"publisher","unstructured":"Luo F, Cao J, Lu F et al. Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. Cancer Cell Int. 2021;21(1):458. Published 2021 Aug 28. https:\/\/doi.org\/10.1186\/s12935-021-02162-w","DOI":"10.1186\/s12935-021-02162-w"},{"issue":"4","key":"3355_CR24","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jtho.2017.11.132","volume":"13","author":"SP Wu","year":"2018","unstructured":"Wu SP, Liao RQ, Tu HY, et al. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1\/PD-L1 Blockade Immunotherapy. J Thorac Oncol. 2018;13(4):521\u201332. https:\/\/doi.org\/10.1016\/j.jtho.2017.11.132.","journal-title":"J Thorac Oncol"},{"key":"3355_CR25","doi-asserted-by":"publisher","unstructured":"Macek Jilkova Z, Aspord C, Decaens T. Predictive Factors for Response to PD-1\/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers (Basel). 2019;11(10):1554. Published 2019 Oct 14. https:\/\/doi.org\/10.3390\/cancers11101554","DOI":"10.3390\/cancers11101554"},{"key":"3355_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12935-019-0738-9","volume":"19","author":"GM Liu","year":"2019","unstructured":"Liu GM, Li XG, Zhang YM. Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell Int. 2019;19:22. https:\/\/doi.org\/10.1186\/s12935-019-0738-9. Published 2019 Jan 29.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"3355_CR27","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s12325-022-02371-3","volume":"40","author":"Y Liu","year":"2023","unstructured":"Liu Y, Pan J, Gao F, Xu W, Li H, Qi X. Efficacy and Safety of PD-1\/PD-L1 Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Adv Ther. 2023;40(2):521\u201349. https:\/\/doi.org\/10.1007\/s12325-022-02371-3.","journal-title":"Adv Ther"},{"issue":"3","key":"3355_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4103\/tcmj.tcmj_159_23","volume":"36","author":"TR Peng","year":"2023","unstructured":"Peng TR, Yang LJ, Wu TW. Efficacy of PD-1\/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis. Tzu Chi Med J. 2023;36(3):340\u20138. https:\/\/doi.org\/10.4103\/tcmj.tcmj_159_23. Published 2023 Nov 7.","journal-title":"Tzu Chi Med J"},{"key":"3355_CR29","doi-asserted-by":"publisher","first-page":"107327482210929","DOI":"10.1177\/10732748221092924","volume":"29","author":"L Zeng","year":"2022","unstructured":"Zeng L, Su J, Qiu W, Jin X, Qiu Y, Yu W. Survival Outcomes and Safety of Programmed Cell Death\/Programmed Cell Death Ligand 1 Inhibitors for Unresectable Hepatocellular Carcinoma: Result From Phase III Trials. Cancer Control. 2022;29:10732748221092924. https:\/\/doi.org\/10.1177\/10732748221092924.","journal-title":"Cancer Control"},{"issue":"6","key":"3355_CR30","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/hep.28710","volume":"64","author":"J Calderaro","year":"2016","unstructured":"Calderaro J, Rousseau B, Amaddeo G, et al. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology. 2016;64(6):2038\u201346. https:\/\/doi.org\/10.1002\/hep.28710.","journal-title":"Hepatology"},{"key":"3355_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/bs.mcb.2024.02.006","volume":"185","author":"D Rep\u00e1raz","year":"2024","unstructured":"Rep\u00e1raz D, Casares N, Fuentes A, Navarro F. Establishment of a murine hepatocellular carcinoma model by hydrodynamic injection and characterization of the immune tumor microenvironment. Methods Cell Biol. 2024;185:79\u201397. https:\/\/doi.org\/10.1016\/bs.mcb.2024.02.006.","journal-title":"Methods Cell Biol"},{"key":"3355_CR32","doi-asserted-by":"publisher","first-page":"122361","DOI":"10.1016\/j.ijpharm.2022.122361","volume":"628","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhao L, Liu H, et al. Norcantharidin liposome emulsion hybrid delivery system enhances PD-1\/PD-L1 immunotherapy by agonizing the non-canonical NF-\u03baB pathway. Int J Pharm. 2022;628:122361. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122361.","journal-title":"Int J Pharm"},{"issue":"5","key":"3355_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12072-020-10064-8","volume":"14","author":"Q Rao","year":"2020","unstructured":"Rao Q, Li M, Xu W, et al. Clinical benefits of PD-1\/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):765\u201375. https:\/\/doi.org\/10.1007\/s12072-020-10064-8.","journal-title":"Hepatol Int"},{"key":"3355_CR34","doi-asserted-by":"publisher","unstructured":"Zhang N, Yang X, Piao M et al. Biomarkers and prognostic factors of PD-1\/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark Res. 2024;12(1):26. Published 2024 Feb 14. https:\/\/doi.org\/10.1186\/s40364-023-00535-z","DOI":"10.1186\/s40364-023-00535-z"},{"key":"3355_CR35","doi-asserted-by":"publisher","unstructured":"Liu B, Shi J, Su R et al. Predicting effect of anti-PD-1\/PD-L1 inhibitors therapy for hepatocellular carcinoma by detecting plasma metabolite based on UHPLC-MS. Front Immunol. 2024;15:1370771. Published 2024 Apr 18. https:\/\/doi.org\/10.3389\/fimmu.2024.1370771","DOI":"10.3389\/fimmu.2024.1370771"},{"issue":"4","key":"3355_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3892\/ol.2021.12540","volume":"21","author":"J Wang","year":"2021","unstructured":"Wang J, Li J, Tang G, Tian Y, Su S, Li Y. Clinical outcomes and influencing factors of PD-1\/PD-L1 in hepatocellular carcinoma. Oncol Lett. 2021;21(4):279. https:\/\/doi.org\/10.3892\/ol.2021.12540.","journal-title":"Oncol Lett"},{"issue":"1","key":"3355_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","volume":"23","author":"T Yau","year":"2022","unstructured":"Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00604-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3355_CR38","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1200\/JCO.19.01307","volume":"38","author":"RS Finn","year":"2020","unstructured":"Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020;38(3):193\u2013202. https:\/\/doi.org\/10.1200\/JCO.19.01307.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3355_CR39","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00262-020-02586-9","volume":"69","author":"Y Yan","year":"2020","unstructured":"Yan Y, Zheng L, Du Q, Yan B, Geller DA. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells. Cancer Immunol Immunother. 2020;69(9):1891\u2013903. https:\/\/doi.org\/10.1007\/s00262-020-02586-9.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"3355_CR40","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1158\/2326-6066.CIR-18-0648","volume":"7","author":"Z Tao","year":"2019","unstructured":"Tao Z, Ruan H, Sun L, et al. Targeting the YB-1\/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Cancer Immunol Res. 2019;7(7):1135\u201347. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0648.","journal-title":"Cancer Immunol Res"},{"key":"3355_CR41","doi-asserted-by":"publisher","first-page":"111601","DOI":"10.1016\/j.intimp.2024.111601","volume":"129","author":"M Song","year":"2024","unstructured":"Song M, Wang L, Jiang S, et al. Pathogenic Th17 cell-mediated liver fibrosis contributes to resistance to PD-L1 antibody immunotherapy in hepatocellular carcinoma. Int Immunopharmacol. 2024;129:111601. https:\/\/doi.org\/10.1016\/j.intimp.2024.111601.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"3355_CR42","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s13402-025-01087-0","volume":"48","author":"X Zhou","year":"2025","unstructured":"Zhou X, Qiao C, Chu X, et al. S100A9 promotes resistance to anti-PD-1 immunotherapy in hepatocellular carcinoma by degrading PARP1 and activating the STAT3\/PD-L1 pathway. Cell Oncol (Dordr). 2025;48(5):1433\u201347. https:\/\/doi.org\/10.1007\/s13402-025-01087-0.","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"3355_CR43","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.21037\/tcr-20-3415","volume":"10","author":"Z Yang","year":"2021","unstructured":"Yang Z, Zhang L, Liu J, et al. PD-L1 combined with HDAC9 is a useful prognostic predictor in hepatocellular carcinoma. Transl Cancer Res. 2021;10(5):2305\u201317. https:\/\/doi.org\/10.21037\/tcr-20-3415.","journal-title":"Transl Cancer Res"},{"issue":"11","key":"3355_CR44","doi-asserted-by":"publisher","first-page":"e007529","DOI":"10.1136\/jitc-2023-007529","volume":"11","author":"R Zhang","year":"2023","unstructured":"Zhang R, Wang J, Du Y, et al. CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma. J Immunother Cancer. 2023;11(11):e007529. https:\/\/doi.org\/10.1136\/jitc-2023-007529. Published 2023 Nov 24.","journal-title":"J Immunother Cancer"},{"key":"3355_CR45","doi-asserted-by":"publisher","first-page":"876048","DOI":"10.3389\/fimmu.2022.876048","volume":"13","author":"X Kong","year":"2022","unstructured":"Kong X, Zheng Z, Song G, et al. Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma. Front Immunol. 2022;13:876048. https:\/\/doi.org\/10.3389\/fimmu.2022.876048. Published 2022 Jun 22.","journal-title":"Front Immunol"},{"key":"3355_CR46","doi-asserted-by":"publisher","first-page":"48","DOI":"10.20517\/cdr.2025.120","volume":"8","author":"Y Chen","year":"2025","unstructured":"Chen Y, Chen D, Liang Z, et al. Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies. Cancer Drug Resist. 2025;8:48. https:\/\/doi.org\/10.20517\/cdr.2025.120. Published 2025 Sep 11.","journal-title":"Cancer Drug Resist"},{"issue":"23","key":"3355_CR47","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.3390\/cancers15235532","volume":"15","author":"AG Singal","year":"2023","unstructured":"Singal AG, \u00d6zg\u00fcrdal K, Fan X, Vassilev Z, Pan X, Multani JK, et al. Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States. Cancers (Basel). 2023;15(23):5532. https:\/\/doi.org\/10.3390\/cancers15235532.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3355_CR48","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000535496","volume":"13","author":"X Liu","year":"2024","unstructured":"Liu X, Lu Y, Zhou W, et al. Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition). Liver Cancer. 2024;13(4):355\u201375. https:\/\/doi.org\/10.1159\/000535496. Published 2024 Jan 16.","journal-title":"Liver Cancer"},{"key":"3355_CR49","doi-asserted-by":"publisher","first-page":"104070","DOI":"10.1016\/j.critrevonc.2023.104070","volume":"189","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zhang Y, Zhang M, et al. Combined immunotherapy for hepatocellular carcinoma: How to maximize immune checkpoint blockade synergic anti-tumor effect. Crit Rev Oncol Hematol. 2023;189:104070. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104070.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3355_CR50","doi-asserted-by":"publisher","unstructured":"Xu J, Zheng Q, Cheng X et al. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. J Nanobiotechnology. 2021;19(1):355. Published 2021 Oct 30. https:\/\/doi.org\/10.1186\/s12951-021-01101-1","DOI":"10.1186\/s12951-021-01101-1"},{"key":"3355_CR51","doi-asserted-by":"publisher","first-page":"175883592513231","DOI":"10.1177\/17588359251323199","volume":"17","author":"LL Chan","year":"2025","unstructured":"Chan LL, Chan SL. Future perspectives on immunotherapy for hepatocellular carcinoma. Ther Adv Med Oncol. 2025;17:17588359251323199. https:\/\/doi.org\/10.1177\/17588359251323199. Published 2025 Mar 25.","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"3355_CR52","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000528272","volume":"12","author":"M Kudo","year":"2022","unstructured":"Kudo M, Finn RS, Galle PR, et al. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022;12(3):238\u201350. https:\/\/doi.org\/10.1159\/000528272. Published 2022 Nov 28.","journal-title":"Liver Cancer"},{"issue":"10","key":"3355_CR53","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.21873\/anticanres.16623","volume":"43","author":"K Yamamura","year":"2023","unstructured":"Yamamura K, Beppu T, Miyata T, et al. Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy. Anticancer Res. 2023;43(10):4285\u201393. https:\/\/doi.org\/10.21873\/anticanres.16623.","journal-title":"Anticancer Res"},{"issue":"10","key":"3355_CR54","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3748\/wjg.v27.i10.919","volume":"27","author":"BM Lee","year":"2021","unstructured":"Lee BM, Seong J. Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. World J Gastroenterol. 2021;27(10):919\u201327. https:\/\/doi.org\/10.3748\/wjg.v27.i10.919.","journal-title":"World J Gastroenterol"},{"key":"3355_CR55","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/ITT.S528709","volume":"14","author":"M Akabane","year":"2025","unstructured":"Akabane M, Chatzipanagiotou OP, Imaoka Y, Schenk A, Pawlik TM. Advancing Adjuvant Immunotherapy in Hepatocellular Carcinoma: A Comprehensive Review. Immunotargets Ther. 2025;14:631\u201354. https:\/\/doi.org\/10.2147\/ITT.S528709. Published 2025 Jun 25.","journal-title":"Immunotargets Ther"},{"issue":"5","key":"3355_CR56","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3892\/ol.2022.13530","volume":"24","author":"M Gryziak","year":"2022","unstructured":"Gryziak M, Wozniak K, Kraj L, Rog L, Stec R. The immune landscape of hepatocellular carcinoma-where we are? Oncol Lett. 2022;24(5):410. https:\/\/doi.org\/10.3892\/ol.2022.13530. Published 2022 Sep 27.","journal-title":"Oncol Lett"},{"key":"3355_CR57","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1016\/j.csbj.2023.11.014","volume":"21","author":"Q Lu","year":"2023","unstructured":"Lu Q, Lou Y, Zhang X, et al. Integrative analysis identified two subtypes and a taurine-related signature to predict the prognosis and efficacy of immunotherapy in hepatocellular carcinoma. Comput Struct Biotechnol J. 2023;21:5561\u201382. https:\/\/doi.org\/10.1016\/j.csbj.2023.11.014. Published 2023 Nov 10.","journal-title":"Comput Struct Biotechnol J"},{"key":"3355_CR58","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/JHC.S322289","volume":"8","author":"B Gok Yavuz","year":"2021","unstructured":"Gok Yavuz B, Hasanov E, Lee SS, et al. Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021;8:1195\u2013207. https:\/\/doi.org\/10.2147\/JHC.S322289. Published 2021 Sep 24.","journal-title":"J Hepatocell Carcinoma"},{"key":"3355_CR59","doi-asserted-by":"publisher","first-page":"1091088","DOI":"10.3389\/fonc.2022.1091088","volume":"12","author":"X Peng","year":"2023","unstructured":"Peng X, Gong C, Zhang W, Zhou A. Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Front Oncol. 2023;12:1091088. https:\/\/doi.org\/10.3389\/fonc.2022.1091088. Published 2023 Jan 16.","journal-title":"Front Oncol"},{"key":"3355_CR60","doi-asserted-by":"publisher","first-page":"1368749","DOI":"10.3389\/fimmu.2024.1368749","volume":"15","author":"Y Qin","year":"2024","unstructured":"Qin Y, Huo M, Liu X, Li SC. Biomarkers and computational models for predicting efficacy to tumor ICI immunotherapy. Front Immunol. 2024;15:1368749. https:\/\/doi.org\/10.3389\/fimmu.2024.1368749. Published 2024 Mar 8.","journal-title":"Front Immunol"},{"issue":"6","key":"3355_CR61","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345\u201362. https:\/\/doi.org\/10.1038\/s41571-021-00473-5.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"3355_CR62","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.3390\/ijms26062794","volume":"26","author":"E Vargas-Accarino","year":"2025","unstructured":"Vargas-Accarino E, Higuera M, Berm\u00fadez-Ramos M, Soriano-Varela A, Torrens M, Pons M, et al. Harnessing Plasma Biomarkers to Predict Immunotherapy Outcomes in Hepatocellular Carcinoma: The Role of cfDNA, ctDNA, and Cytokines. Int J Mol Sci. 2025;26(6):2794. https:\/\/doi.org\/10.3390\/ijms26062794.","journal-title":"Int J Mol Sci"},{"key":"3355_CR63","doi-asserted-by":"publisher","first-page":"e008953","DOI":"10.1136\/jitc-2024-008953","volume":"12","author":"Y Hua","year":"2024","unstructured":"Hua Y, Sun Z, Xiao Y, Li H, Ma X, Luo X, et al. Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy. J Immunother Cancer. 2024;12:e008953. https:\/\/doi.org\/10.1136\/jitc-2024-008953.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3355_CR64","doi-asserted-by":"publisher","first-page":"e004779","DOI":"10.1136\/jitc-2022-004779","volume":"10","author":"PC Lee","year":"2022","unstructured":"Lee PC, Wu CJ, Hung YW, Lee CJ, Chi CT, Lee IC, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022;10(6):e004779. https:\/\/doi.org\/10.1136\/jitc-2022-004779.","journal-title":"J Immunother Cancer"},{"key":"3355_CR65","doi-asserted-by":"publisher","first-page":"20027","DOI":"10.1038\/s41598-024-70208-w","volume":"14","author":"L Qi","year":"2024","unstructured":"Qi L, Zhu Y, Li J, Zhou M, Liu B, Chen J, et al. CT radiomics-based biomarkers can predict response to immunotherapy in hepatocellular carcinoma. Sci Rep. 2024;14:20027. https:\/\/doi.org\/10.1038\/s41598-024-70208-w.","journal-title":"Sci Rep"},{"key":"3355_CR66","doi-asserted-by":"publisher","first-page":"698373","DOI":"10.3389\/fonc.2021.698373","volume":"11","author":"XQ Gong","year":"2021","unstructured":"Gong XQ, Tao YY, Wu YK, Liu N, Yu X, Wang R, et al. Progress of MRI Radiomics in Hepatocellular Carcinoma. Front Oncol. 2021;11:698373. https:\/\/doi.org\/10.3389\/fonc.2021.698373.","journal-title":"Front Oncol"},{"key":"3355_CR67","doi-asserted-by":"publisher","first-page":"1679365","DOI":"10.3389\/fimmu.2025.1679365","volume":"16","author":"J Ma","year":"2025","unstructured":"Ma J, Wu D, Liu Y, Zhang G. Advancing immunotherapy for esophageal cancer: decoding the roles of PD-L1, TME, and tumor-intrinsic biomarkers. Front Immunol. 2025;16:1679365. https:\/\/doi.org\/10.3389\/fimmu.2025.1679365. Published 2025 Nov 18.","journal-title":"Front Immunol"},{"issue":"4","key":"3355_CR68","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.3390\/ijms24043441","volume":"24","author":"D Gabbia","year":"2023","unstructured":"Gabbia D, De Martin S. Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. Int J Mol Sci. 2023;24(4):3441. https:\/\/doi.org\/10.3390\/ijms24043441. Published 2023 Feb 8.","journal-title":"Int J Mol Sci"},{"key":"3355_CR69","doi-asserted-by":"publisher","first-page":"1601188","DOI":"10.3389\/fimmu.2025.1601188","volume":"16","author":"JA Lee","year":"2025","unstructured":"Lee JA, Park HE, Lee DW, et al. Immunogenomic characteristics and prognostic implications of terminally exhausted CD8\u2009+\u2009T cells in colorectal cancers. Front Immunol. 2025;16:1601188. https:\/\/doi.org\/10.3389\/fimmu.2025.1601188. Published 2025 May 30.","journal-title":"Front Immunol"},{"issue":"5","key":"3355_CR70","doi-asserted-by":"publisher","first-page":"e756","DOI":"10.1002\/onco.13695","volume":"26","author":"P Yu","year":"2021","unstructured":"Yu P, Wang Y, Yu Y, et al. Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma. Oncologist. 2021;26(5):e756\u201368. https:\/\/doi.org\/10.1002\/onco.13695.","journal-title":"Oncologist"},{"issue":"22","key":"3355_CR71","doi-asserted-by":"publisher","first-page":"4591","DOI":"10.26355\/eurrev_202411_36955","volume":"28","author":"YM Zhang","year":"2024","unstructured":"Zhang YM, Fan JK, Wang XY, et al. Study on MKNK2 as a potential prognostic and immunological biomarker in pan-cancer. Eur Rev Med Pharmacol Sci. 2024;28(22):4591\u2013620. https:\/\/doi.org\/10.26355\/eurrev_202411_36955.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"3355_CR72","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12859-025-06125-0","volume":"26","author":"D Lee","year":"2025","unstructured":"Lee D, Ahn J, Choi J. PathNetDRP: a novel biomarker discovery framework using pathway and protein-protein interaction networks for immune checkpoint inhibitor response prediction. BMC Bioinformatics. 2025;26(1):119. https:\/\/doi.org\/10.1186\/s12859-025-06125-0. Published 2025 May 5.","journal-title":"BMC Bioinformatics"},{"issue":"10","key":"3355_CR73","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.bulcan.2022.07.002","volume":"109","author":"A Zaanan","year":"2022","unstructured":"Zaanan A. Immunoth\u00e9rapie dans le traitement du cancer gastrique m\u00e9tastatique [Immunotherapy in advanced gastric cancer]. Bull Cancer. 2022;109(10):1066\u201372. https:\/\/doi.org\/10.1016\/j.bulcan.2022.07.002.","journal-title":"Bull Cancer"},{"issue":"19","key":"3355_CR74","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.3390\/cancers15194677","volume":"15","author":"Y Chen","year":"2023","unstructured":"Chen Y, Yang C, Sheng L, Jiang H, Song B. The Era of Immunotherapy in Hepatocellular Carcinoma: The New Mission and Challenges of Magnetic Resonance Imaging. Cancers (Basel). 2023;15(19):4677. https:\/\/doi.org\/10.3390\/cancers15194677. Published 2023 Sep 22.","journal-title":"Cancers (Basel)"},{"key":"3355_CR75","doi-asserted-by":"publisher","first-page":"938796","DOI":"10.3389\/fgene.2022.938796","volume":"13","author":"Y Xia","year":"2022","unstructured":"Xia Y, Lin X, Cheng Y, et al. Characterization of Platelet Function-Related Gene Predicting Survival and Immunotherapy Efficacy in Gastric Cancer. Front Genet. 2022;13:938796. https:\/\/doi.org\/10.3389\/fgene.2022.938796. Published 2022 Jun 28.","journal-title":"Front Genet"},{"key":"3355_CR76","doi-asserted-by":"publisher","first-page":"716844","DOI":"10.3389\/fonc.2021.716844","volume":"11","author":"Y He","year":"2021","unstructured":"He Y, Lu M, Che J, Chu Q, Zhang P, Chen Y. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. Front Oncol. 2021;11:716844. https:\/\/doi.org\/10.3389\/fonc.2021.716844. Published 2021 Sep 6.","journal-title":"Front Oncol"},{"key":"3355_CR77","doi-asserted-by":"publisher","first-page":"1568962","DOI":"10.3389\/fimmu.2025.1568962","volume":"16","author":"PJ Chen","year":"2025","unstructured":"Chen PJ, Devkota S, Shiao S, Hendifar A, Yang JD. Gut microbiome, a novel precision medicine biomarker for hepatocellular carcinoma. Front Immunol. 2025;16:1568962. https:\/\/doi.org\/10.3389\/fimmu.2025.1568962. Published 2025 Dec 8.","journal-title":"Front Immunol"},{"issue":"1","key":"3355_CR78","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","volume":"7","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019;7(1):193. https:\/\/doi.org\/10.1186\/s40425-019-0650-9. Published 2019 Jul 23.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"3355_CR79","doi-asserted-by":"publisher","first-page":"e004779","DOI":"10.1136\/jitc-2022-004779","volume":"10","author":"PC Lee","year":"2022","unstructured":"Lee PC, Wu CJ, Hung YW, et al. Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022;10(6):e004779. https:\/\/doi.org\/10.1136\/jitc-2022-004779.","journal-title":"J Immunother Cancer"},{"key":"3355_CR80","doi-asserted-by":"publisher","first-page":"1366131","DOI":"10.3389\/fgene.2024.1366131","volume":"15","author":"Y Xin","year":"2024","unstructured":"Xin Y, Peng G, Song W, Zhou X, Huang X, Cao X. Gut microbiota as a prognostic biomarker for unresectable hepatocellular carcinoma treated with anti-PD-1 therapy. Front Genet. 2024;15:1366131. https:\/\/doi.org\/10.3389\/fgene.2024.1366131. Published 2024 Oct 3.","journal-title":"Front Genet"},{"issue":"10","key":"3355_CR81","doi-asserted-by":"publisher","first-page":"102370","DOI":"10.1016\/j.xcrm.2025.102370","volume":"6","author":"CN Zhao","year":"2025","unstructured":"Zhao CN, Li SS, Yau T, et al. Phocaeicola vulgatus induces immunotherapy resistance in hepatocellular carcinoma via reducing indoleacetic acid production. Cell Rep Med. 2025;6(10):102370. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102370.","journal-title":"Cell Rep Med"},{"issue":"10","key":"3355_CR82","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1080\/1744666X.2025.2568904","volume":"21","author":"M Akabane","year":"2025","unstructured":"Akabane M, Imaoka Y, Lee GR, Pawlik TM. Immunology, immunotherapy, and the tumor microenvironment in hepatocellular carcinoma: a comprehensive review. Expert Rev Clin Immunol. 2025;21(10):1403\u201320. https:\/\/doi.org\/10.1080\/1744666X.2025.2568904.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"3355_CR83","doi-asserted-by":"publisher","first-page":"2313696","DOI":"10.1080\/15476278.2024.2313696","volume":"20","author":"BM Lehrich","year":"2024","unstructured":"Lehrich BM, Delgado ER. Lipid Nanovesicle Platforms for Hepatocellular Carcinoma Precision Medicine Therapeutics: Progress and Perspectives. Organogenesis. 2024;20(1):2313696. https:\/\/doi.org\/10.1080\/15476278.2024.2313696.","journal-title":"Organogenesis"},{"issue":"9","key":"3355_CR84","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.32604\/or.2025.063719","volume":"33","author":"J Xue","year":"2025","unstructured":"Xue J, Zhang J, Chen G, Chen L, Lu X. Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma. Oncol Res. 2025;33(9):2309\u201329. https:\/\/doi.org\/10.32604\/or.2025.063719. Published 2025 Aug 28.","journal-title":"Oncol Res"},{"issue":"1","key":"3355_CR85","doi-asserted-by":"publisher","first-page":"100957","DOI":"10.1016\/j.tranon.2020.100957","volume":"14","author":"Y Xu","year":"2021","unstructured":"Xu Y, Wang Z, Li F. Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma. Transl Oncol. 2021;14(1):100957. https:\/\/doi.org\/10.1016\/j.tranon.2020.100957.","journal-title":"Transl Oncol"},{"issue":"6","key":"3355_CR86","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3892\/ol.2025.15322","volume":"30","author":"CH Hsieh","year":"2025","unstructured":"Hsieh CH, Chuang PC. Immune checkpoint biology in hepatocellular carcinoma (Review). Oncol Lett. 2025;30(6):576. https:\/\/doi.org\/10.3892\/ol.2025.15322. Published 2025 Oct 7.","journal-title":"Oncol Lett"},{"issue":"20","key":"3355_CR87","doi-asserted-by":"publisher","first-page":"11091","DOI":"10.3390\/ijms252011091","volume":"25","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Brunetti O, Brandi G. Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges. Int J Mol Sci. 2024;25(20):11091. https:\/\/doi.org\/10.3390\/ijms252011091. Published 2024 Oct 15.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3355_CR88","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/s-0043-1776127","volume":"43","author":"X Han","year":"2023","unstructured":"Han X, Sun Q, Xu M, et al. Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Semin Liver Dis. 2023;43(4):383\u2013401. https:\/\/doi.org\/10.1055\/s-0043-1776127.","journal-title":"Semin Liver Dis"},{"issue":"2","key":"3355_CR89","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1055\/s-0040-1722646","volume":"41","author":"PLS Uson Junior","year":"2021","unstructured":"Uson Junior PLS, Nagalo BM, Ahn DH, Bekaii-Saab T, Borad MJ. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently? Semin Liver Dis. 2021;41(2):136\u201341. https:\/\/doi.org\/10.1055\/s-0040-1722646.","journal-title":"Semin Liver Dis"},{"issue":"14","key":"3355_CR90","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/s41388-023-02646-1","volume":"42","author":"M Akce","year":"2023","unstructured":"Akce M, El-Rayes BF, Wajapeyee N. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy. Oncogene. 2023;42(14):1051\u20137. https:\/\/doi.org\/10.1038\/s41388-023-02646-1.","journal-title":"Oncogene"},{"key":"3355_CR91","doi-asserted-by":"publisher","first-page":"101234","DOI":"10.1016\/j.neo.2025.101234","volume":"69","author":"T Nosaka","year":"2025","unstructured":"Nosaka T, Ohtani M, Yamashita J, et al. PD-L1(+) tumor-associated macrophages induce CD8(+) T Cell exhaustion in hepatocellular carcinoma. Neoplasia. 2025;69:101234. https:\/\/doi.org\/10.1016\/j.neo.2025.101234.","journal-title":"Neoplasia"},{"issue":"11","key":"3355_CR92","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1158\/2326-6066.CIR-23-0627","volume":"12","author":"X Xiang","year":"2024","unstructured":"Xiang X, Wang K, Zhang H, et al. Blocking CX3CR1\u2009+\u2009Tumor-Associated Macrophages Enhances the Efficacy of Anti-PD1 Therapy in Hepatocellular Carcinoma. Cancer Immunol Res. 2024;12(11):1603\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-23-0627.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3355_CR93","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13046-025-03490-9","volume":"44","author":"F Liu","year":"2025","unstructured":"Liu F, Li X, Zhang Y, et al. Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma. J Exp Clin Cancer Res. 2025;44(1):227. https:\/\/doi.org\/10.1186\/s13046-025-03490-9. Published 2025 Aug 5.","journal-title":"J Exp Clin Cancer Res"},{"key":"3355_CR94","doi-asserted-by":"publisher","first-page":"114318","DOI":"10.1016\/j.colsurfb.2024.114318","volume":"245","author":"J Du","year":"2025","unstructured":"Du J, Que Z, Aihaiti A, et al. Co-delivery of SN38 and MEF2D-siRNA via tLyp-1-modified liposomes reverses PD-L1 expression induced by STING activation in hepatocellular carcinoma. Colloids Surf B Biointerfaces. 2025;245:114318. https:\/\/doi.org\/10.1016\/j.colsurfb.2024.114318.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3355_CR95","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y, Targeting. LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16:101. https:\/\/doi.org\/10.1186\/s13045-023-01499-1.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"3355_CR96","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322. https:\/\/doi.org\/10.1016\/j.immuni.2024.01.010.","journal-title":"Immunity"},{"key":"3355_CR97","doi-asserted-by":"publisher","unstructured":"Finn RS, Ryoo BY, Hsu CH et al. Results from the MORPHEUS-liver study: Phase Ib\/II randomized evaluation of tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma. J Clin Oncol 41, 4010-40100. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.4010","DOI":"10.1200\/JCO.2023.41.16_suppl.4010"},{"issue":"10","key":"3355_CR98","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.immuni.2023.07.018","volume":"56","author":"LL Cao","year":"2023","unstructured":"Cao LL, Kagan JC. Targeting innate immune pathways for cancer immunotherapy. Immunity. 2023;56(10):2206\u201317. https:\/\/doi.org\/10.1016\/j.immuni.2023.07.018.","journal-title":"Immunity"},{"key":"3355_CR99","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1146\/annurev-immunol-101721-032910","volume":"43","author":"B Zhang","year":"2025","unstructured":"Zhang B, Xu P, Ablasser A. Regulation of the cGAS-STING pathway. Annu Rev Immunol. 2025;43:667\u201392. https:\/\/doi.org\/10.1146\/annurev-immunol-101721-032910.","journal-title":"Annu Rev Immunol"},{"key":"3355_CR100","doi-asserted-by":"publisher","unstructured":"Myojin Y, Hikita H et al. Adenosine A2A receptor inhibition increases the anti-tumor efficacy of immune checkpoint inhibitors in murine models of liver cancer. J Hepatol6 (1): 100959-100959. 2023. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100959","DOI":"10.1016\/j.jhepr.2023.100959"},{"key":"3355_CR101","doi-asserted-by":"publisher","unstructured":"Peng X, He Z, Yuan D, Liu Z, Rong P. Lactic acid: The culprit behind the immunosuppressive microenvironment in hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(5):189164. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189164","DOI":"10.1016\/j.bbcan.2024.189164"},{"issue":"3","key":"3355_CR102","doi-asserted-by":"publisher","first-page":"e004414","DOI":"10.1136\/jitc-2021-004414","volume":"10","author":"X Wang","year":"2022","unstructured":"Wang X, Zhou T, Chen X, et al. System analysis based on the cancer-immunity cycle identifies ZNF207 as a novel immunotherapy target for hepatocellular carcinoma. J Immunother Cancer. 2022;10(3):e004414. https:\/\/doi.org\/10.1136\/jitc-2021-004414.","journal-title":"J Immunother Cancer"},{"key":"3355_CR103","doi-asserted-by":"publisher","first-page":"706915","DOI":"10.3389\/fonc.2021.706915","volume":"11","author":"Y Nie","year":"2021","unstructured":"Nie Y, Li J, Wu W, et al. A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma. Front Oncol. 2021;11:706915. https:\/\/doi.org\/10.3389\/fonc.2021.706915. Published 2021 Sep 15.","journal-title":"Front Oncol"},{"issue":"7","key":"3355_CR104","doi-asserted-by":"publisher","first-page":"106810","DOI":"10.4254\/wjh.v17.i7.106810","volume":"17","author":"KMN Pamungkas","year":"2025","unstructured":"Pamungkas KMN, Lesmana Dewi PIS, Alamsyah AZ, et al. Microbiome dysbiosis and immune checkpoint inhibitors: Dual targets in Hepatocellular carcinoma management. World J Hepatol. 2025;17(7):106810. https:\/\/doi.org\/10.4254\/wjh.v17.i7.106810.","journal-title":"World J Hepatol"},{"issue":"20","key":"3355_CR105","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.3748\/wjg.v28.i20.2248","volume":"28","author":"YB Kang","year":"2022","unstructured":"Kang YB, Cai Y. Future prospect of Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients. World J Gastroenterol. 2022;28(20):2248\u201350. https:\/\/doi.org\/10.3748\/wjg.v28.i20.2248.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3355_CR106","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1186\/s12885-023-11678-5","volume":"23","author":"R Zhang","year":"2023","unstructured":"Zhang R, Zhao H, Wang P, Guo Z, Liu C, Qu Z. Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors. BMC Cancer. 2023;23(1):1181. https:\/\/doi.org\/10.1186\/s12885-023-11678-5. Published 2023 Dec 1.","journal-title":"BMC Cancer"},{"key":"3355_CR107","doi-asserted-by":"publisher","first-page":"997314","DOI":"10.3389\/fonc.2023.997314","volume":"13","author":"Q Li","year":"2023","unstructured":"Li Q, Ma F, Wang JF. Advanced lung cancer inflammation index predicts survival outcomes of hepatocellular carcinoma patients receiving immunotherapy. Front Oncol. 2023;13:997314. https:\/\/doi.org\/10.3389\/fonc.2023.997314. Published 2023 Mar 14.","journal-title":"Front Oncol"},{"issue":"15","key":"3355_CR108","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.3390\/ijms22157800","volume":"22","author":"S Temraz","year":"2021","unstructured":"Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. Int J Mol Sci. 2021;22(15):7800. https:\/\/doi.org\/10.3390\/ijms22157800. Published 2021 Jul 21.","journal-title":"Int J Mol Sci"},{"key":"3355_CR109","doi-asserted-by":"publisher","first-page":"1028728","DOI":"10.3389\/fonc.2022.1028728","volume":"12","author":"PS Sung","year":"2022","unstructured":"Sung PS, Lee IK, Roh PR, Kang MW, Ahn J, Yoon SK. Blood-based biomarkers for immune-based therapy in advanced HCC: Promising but a long way to go. Front Oncol. 2022;12:1028728. https:\/\/doi.org\/10.3389\/fonc.2022.1028728. Published 2022 Oct 31.","journal-title":"Front Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03355-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03355-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03355-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:21:19Z","timestamp":1788924079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-026-03355-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":109,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["3355"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03355-x","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The first author's affiliation has been corrected","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"239"}}